nodes	percent_of_prediction	percent_of_DWPC	metapath
Nevirapine—acquired immunodeficiency syndrome—sarcoma	0.731	1	CtDrD
Nevirapine—CYP2B6—Thiotepa—sarcoma	0.0733	0.348	CbGbCtD
Nevirapine—CYP1A2—Dacarbazine—sarcoma	0.0238	0.113	CbGbCtD
Nevirapine—CYP3A4—Thiotepa—sarcoma	0.0225	0.107	CbGbCtD
Nevirapine—CYP3A5—Vincristine—sarcoma	0.0171	0.0811	CbGbCtD
Nevirapine—CYP3A5—Etoposide—sarcoma	0.0157	0.0743	CbGbCtD
Nevirapine—CYP2B6—Doxorubicin—sarcoma	0.0136	0.0643	CbGbCtD
Nevirapine—CYP1A2—Etoposide—sarcoma	0.0117	0.0553	CbGbCtD
Nevirapine—CYP3A4—Mitoxantrone—sarcoma	0.00969	0.0459	CbGbCtD
Nevirapine—CYP3A4—Vincristine—sarcoma	0.00667	0.0316	CbGbCtD
Nevirapine—CYP2D6—Doxorubicin—sarcoma	0.00655	0.0311	CbGbCtD
Nevirapine—CYP3A4—Etoposide—sarcoma	0.00611	0.029	CbGbCtD
Nevirapine—CYP3A4—Doxorubicin—sarcoma	0.00417	0.0198	CbGbCtD
Nevirapine—Discomfort—Dactinomycin—sarcoma	0.000175	0.00299	CcSEcCtD
Nevirapine—Mouth ulceration—Epirubicin—sarcoma	0.000174	0.00298	CcSEcCtD
Nevirapine—Anaemia—Vincristine—sarcoma	0.000172	0.00294	CcSEcCtD
Nevirapine—Skin exfoliation—Doxorubicin—sarcoma	0.00017	0.00292	CcSEcCtD
Nevirapine—Oedema—Dactinomycin—sarcoma	0.00017	0.0029	CcSEcCtD
Nevirapine—Ill-defined disorder—Mitoxantrone—sarcoma	0.000168	0.00287	CcSEcCtD
Nevirapine—Nervous system disorder—Thiotepa—sarcoma	0.000168	0.00287	CcSEcCtD
Nevirapine—Thrombocytopenia—Thiotepa—sarcoma	0.000167	0.00286	CcSEcCtD
Nevirapine—Anaemia—Mitoxantrone—sarcoma	0.000167	0.00286	CcSEcCtD
Nevirapine—Thrombocytopenia—Dactinomycin—sarcoma	0.000166	0.00284	CcSEcCtD
Nevirapine—Skin disorder—Thiotepa—sarcoma	0.000166	0.00284	CcSEcCtD
Nevirapine—Lymphadenopathy—Epirubicin—sarcoma	0.000164	0.00281	CcSEcCtD
Nevirapine—Erythema multiforme—Etoposide—sarcoma	0.000163	0.0028	CcSEcCtD
Nevirapine—Malaise—Mitoxantrone—sarcoma	0.000163	0.00279	CcSEcCtD
Nevirapine—Anorexia—Thiotepa—sarcoma	0.000163	0.00279	CcSEcCtD
Nevirapine—Rash maculo-papular—Doxorubicin—sarcoma	0.000162	0.00278	CcSEcCtD
Nevirapine—Anorexia—Dactinomycin—sarcoma	0.000162	0.00277	CcSEcCtD
Nevirapine—Mouth ulceration—Doxorubicin—sarcoma	0.000161	0.00276	CcSEcCtD
Nevirapine—Myalgia—Vincristine—sarcoma	0.000158	0.00271	CcSEcCtD
Nevirapine—Immune system disorder—Etoposide—sarcoma	0.000156	0.00267	CcSEcCtD
Nevirapine—Hepatic failure—Epirubicin—sarcoma	0.000156	0.00267	CcSEcCtD
Nevirapine—Musculoskeletal discomfort—Thiotepa—sarcoma	0.000156	0.00266	CcSEcCtD
Nevirapine—Musculoskeletal discomfort—Dactinomycin—sarcoma	0.000155	0.00264	CcSEcCtD
Nevirapine—Arthralgia—Mitoxantrone—sarcoma	0.000154	0.00263	CcSEcCtD
Nevirapine—Myalgia—Mitoxantrone—sarcoma	0.000154	0.00263	CcSEcCtD
Nevirapine—Paraesthesia—Thiotepa—sarcoma	0.000153	0.00263	CcSEcCtD
Nevirapine—Discomfort—Mitoxantrone—sarcoma	0.000152	0.0026	CcSEcCtD
Nevirapine—Somnolence—Thiotepa—sarcoma	0.000152	0.0026	CcSEcCtD
Nevirapine—Lymphadenopathy—Doxorubicin—sarcoma	0.000152	0.0026	CcSEcCtD
Nevirapine—Anaphylactic shock—Vincristine—sarcoma	0.000152	0.00259	CcSEcCtD
Nevirapine—Oedema—Vincristine—sarcoma	0.000152	0.00259	CcSEcCtD
Nevirapine—Nervous system disorder—Vincristine—sarcoma	0.000149	0.00254	CcSEcCtD
Nevirapine—Decreased appetite—Thiotepa—sarcoma	0.000149	0.00254	CcSEcCtD
Nevirapine—Dermatitis exfoliative—Epirubicin—sarcoma	0.000148	0.00254	CcSEcCtD
Nevirapine—Thrombocytopenia—Vincristine—sarcoma	0.000148	0.00254	CcSEcCtD
Nevirapine—Anaphylactic shock—Mitoxantrone—sarcoma	0.000148	0.00253	CcSEcCtD
Nevirapine—Oedema—Mitoxantrone—sarcoma	0.000148	0.00253	CcSEcCtD
Nevirapine—Gastrointestinal disorder—Thiotepa—sarcoma	0.000148	0.00253	CcSEcCtD
Nevirapine—Decreased appetite—Dactinomycin—sarcoma	0.000147	0.00252	CcSEcCtD
Nevirapine—Fatigue—Thiotepa—sarcoma	0.000147	0.00252	CcSEcCtD
Nevirapine—Dermatitis bullous—Epirubicin—sarcoma	0.000146	0.00251	CcSEcCtD
Nevirapine—Fatigue—Dactinomycin—sarcoma	0.000146	0.0025	CcSEcCtD
Nevirapine—Pain—Thiotepa—sarcoma	0.000146	0.0025	CcSEcCtD
Nevirapine—Pain—Dactinomycin—sarcoma	0.000145	0.00248	CcSEcCtD
Nevirapine—Thrombocytopenia—Mitoxantrone—sarcoma	0.000145	0.00247	CcSEcCtD
Nevirapine—Anorexia—Vincristine—sarcoma	0.000144	0.00247	CcSEcCtD
Nevirapine—Hepatic failure—Doxorubicin—sarcoma	0.000144	0.00247	CcSEcCtD
Nevirapine—Skin disorder—Mitoxantrone—sarcoma	0.000143	0.00245	CcSEcCtD
Nevirapine—Feeling abnormal—Thiotepa—sarcoma	0.000141	0.00241	CcSEcCtD
Nevirapine—Anorexia—Mitoxantrone—sarcoma	0.000141	0.00241	CcSEcCtD
Nevirapine—Feeling abnormal—Dactinomycin—sarcoma	0.00014	0.00239	CcSEcCtD
Nevirapine—Gastrointestinal pain—Thiotepa—sarcoma	0.00014	0.00239	CcSEcCtD
Nevirapine—Ill-defined disorder—Etoposide—sarcoma	0.00014	0.00239	CcSEcCtD
Nevirapine—Anaemia—Etoposide—sarcoma	0.000139	0.00238	CcSEcCtD
Nevirapine—Gastrointestinal pain—Dactinomycin—sarcoma	0.000139	0.00237	CcSEcCtD
Nevirapine—Musculoskeletal discomfort—Vincristine—sarcoma	0.000138	0.00236	CcSEcCtD
Nevirapine—Dermatitis exfoliative—Doxorubicin—sarcoma	0.000137	0.00235	CcSEcCtD
Nevirapine—Paraesthesia—Vincristine—sarcoma	0.000136	0.00233	CcSEcCtD
Nevirapine—Urticaria—Thiotepa—sarcoma	0.000136	0.00232	CcSEcCtD
Nevirapine—Malaise—Etoposide—sarcoma	0.000136	0.00232	CcSEcCtD
Nevirapine—Dermatitis bullous—Doxorubicin—sarcoma	0.000136	0.00232	CcSEcCtD
Nevirapine—Face oedema—Epirubicin—sarcoma	0.000135	0.00231	CcSEcCtD
Nevirapine—Abdominal pain—Thiotepa—sarcoma	0.000135	0.00231	CcSEcCtD
Nevirapine—Body temperature increased—Thiotepa—sarcoma	0.000135	0.00231	CcSEcCtD
Nevirapine—Musculoskeletal discomfort—Mitoxantrone—sarcoma	0.000134	0.0023	CcSEcCtD
Nevirapine—Body temperature increased—Dactinomycin—sarcoma	0.000134	0.00229	CcSEcCtD
Nevirapine—Abdominal pain—Dactinomycin—sarcoma	0.000134	0.00229	CcSEcCtD
Nevirapine—Paraesthesia—Mitoxantrone—sarcoma	0.000133	0.00227	CcSEcCtD
Nevirapine—Decreased appetite—Vincristine—sarcoma	0.000132	0.00225	CcSEcCtD
Nevirapine—Somnolence—Mitoxantrone—sarcoma	0.000131	0.00225	CcSEcCtD
Nevirapine—Gastrointestinal disorder—Vincristine—sarcoma	0.000131	0.00224	CcSEcCtD
Nevirapine—Fatigue—Vincristine—sarcoma	0.000131	0.00224	CcSEcCtD
Nevirapine—Pain—Vincristine—sarcoma	0.00013	0.00222	CcSEcCtD
Nevirapine—Liver function test abnormal—Epirubicin—sarcoma	0.000129	0.00221	CcSEcCtD
Nevirapine—Decreased appetite—Mitoxantrone—sarcoma	0.000128	0.0022	CcSEcCtD
Nevirapine—Fatigue—Mitoxantrone—sarcoma	0.000127	0.00218	CcSEcCtD
Nevirapine—Unspecified disorder of skin and subcutaneous tissue—Etoposide—sarcoma	0.000127	0.00218	CcSEcCtD
Nevirapine—Discomfort—Etoposide—sarcoma	0.000127	0.00217	CcSEcCtD
Nevirapine—Pain—Mitoxantrone—sarcoma	0.000126	0.00216	CcSEcCtD
Nevirapine—Toxic epidermal necrolysis—Epirubicin—sarcoma	0.000126	0.00216	CcSEcCtD
Nevirapine—Aspartate aminotransferase increased—Epirubicin—sarcoma	0.000126	0.00216	CcSEcCtD
Nevirapine—Hypersensitivity—Thiotepa—sarcoma	0.000126	0.00215	CcSEcCtD
Nevirapine—Face oedema—Doxorubicin—sarcoma	0.000125	0.00214	CcSEcCtD
Nevirapine—Hypersensitivity—Dactinomycin—sarcoma	0.000125	0.00214	CcSEcCtD
Nevirapine—Gastrointestinal pain—Vincristine—sarcoma	0.000124	0.00212	CcSEcCtD
Nevirapine—Alanine aminotransferase increased—Epirubicin—sarcoma	0.000123	0.00211	CcSEcCtD
Nevirapine—Anaphylactic shock—Etoposide—sarcoma	0.000123	0.0021	CcSEcCtD
Nevirapine—Asthenia—Thiotepa—sarcoma	0.000123	0.0021	CcSEcCtD
Nevirapine—Asthenia—Dactinomycin—sarcoma	0.000122	0.00208	CcSEcCtD
Nevirapine—Feeling abnormal—Mitoxantrone—sarcoma	0.000122	0.00208	CcSEcCtD
Nevirapine—Pruritus—Thiotepa—sarcoma	0.000121	0.00207	CcSEcCtD
Nevirapine—Gastrointestinal pain—Mitoxantrone—sarcoma	0.000121	0.00207	CcSEcCtD
Nevirapine—Thrombocytopenia—Etoposide—sarcoma	0.00012	0.00206	CcSEcCtD
Nevirapine—Eosinophilia—Epirubicin—sarcoma	0.00012	0.00205	CcSEcCtD
Nevirapine—Abdominal pain—Vincristine—sarcoma	0.00012	0.00205	CcSEcCtD
Nevirapine—Body temperature increased—Vincristine—sarcoma	0.00012	0.00205	CcSEcCtD
Nevirapine—Liver function test abnormal—Doxorubicin—sarcoma	0.00012	0.00205	CcSEcCtD
Nevirapine—Skin disorder—Etoposide—sarcoma	0.000119	0.00204	CcSEcCtD
Nevirapine—Pancreatitis—Epirubicin—sarcoma	0.000119	0.00203	CcSEcCtD
Nevirapine—Urticaria—Mitoxantrone—sarcoma	0.000117	0.00201	CcSEcCtD
Nevirapine—Anorexia—Etoposide—sarcoma	0.000117	0.002	CcSEcCtD
Nevirapine—Diarrhoea—Thiotepa—sarcoma	0.000117	0.002	CcSEcCtD
Nevirapine—Abdominal pain—Mitoxantrone—sarcoma	0.000117	0.002	CcSEcCtD
Nevirapine—Body temperature increased—Mitoxantrone—sarcoma	0.000117	0.002	CcSEcCtD
Nevirapine—Toxic epidermal necrolysis—Doxorubicin—sarcoma	0.000117	0.002	CcSEcCtD
Nevirapine—Aspartate aminotransferase increased—Doxorubicin—sarcoma	0.000117	0.002	CcSEcCtD
Nevirapine—Diarrhoea—Dactinomycin—sarcoma	0.000116	0.00199	CcSEcCtD
Nevirapine—Alanine aminotransferase increased—Doxorubicin—sarcoma	0.000114	0.00196	CcSEcCtD
Nevirapine—Neutropenia—Epirubicin—sarcoma	0.000113	0.00194	CcSEcCtD
Nevirapine—Hypersensitivity—Vincristine—sarcoma	0.000112	0.00191	CcSEcCtD
Nevirapine—Eosinophilia—Doxorubicin—sarcoma	0.000111	0.0019	CcSEcCtD
Nevirapine—Paraesthesia—Etoposide—sarcoma	0.00011	0.00189	CcSEcCtD
Nevirapine—Pancreatitis—Doxorubicin—sarcoma	0.00011	0.00188	CcSEcCtD
Nevirapine—Hyperglycaemia—Epirubicin—sarcoma	0.000109	0.00187	CcSEcCtD
Nevirapine—Somnolence—Etoposide—sarcoma	0.000109	0.00187	CcSEcCtD
Nevirapine—Hypersensitivity—Mitoxantrone—sarcoma	0.000109	0.00186	CcSEcCtD
Nevirapine—Asthenia—Vincristine—sarcoma	0.000109	0.00186	CcSEcCtD
Nevirapine—Vomiting—Thiotepa—sarcoma	0.000109	0.00186	CcSEcCtD
Nevirapine—Vomiting—Dactinomycin—sarcoma	0.000108	0.00185	CcSEcCtD
Nevirapine—Rash—Thiotepa—sarcoma	0.000108	0.00184	CcSEcCtD
Nevirapine—Dermatitis—Thiotepa—sarcoma	0.000108	0.00184	CcSEcCtD
Nevirapine—Headache—Thiotepa—sarcoma	0.000107	0.00183	CcSEcCtD
Nevirapine—Stevens-Johnson syndrome—Epirubicin—sarcoma	0.000107	0.00183	CcSEcCtD
Nevirapine—Rash—Dactinomycin—sarcoma	0.000107	0.00183	CcSEcCtD
Nevirapine—Decreased appetite—Etoposide—sarcoma	0.000107	0.00183	CcSEcCtD
Nevirapine—Renal failure—Epirubicin—sarcoma	0.000106	0.00182	CcSEcCtD
Nevirapine—Gastrointestinal disorder—Etoposide—sarcoma	0.000106	0.00181	CcSEcCtD
Nevirapine—Asthenia—Mitoxantrone—sarcoma	0.000106	0.00181	CcSEcCtD
Nevirapine—Fatigue—Etoposide—sarcoma	0.000106	0.00181	CcSEcCtD
Nevirapine—Neuropathy peripheral—Epirubicin—sarcoma	0.000106	0.00181	CcSEcCtD
Nevirapine—Jaundice—Epirubicin—sarcoma	0.000105	0.0018	CcSEcCtD
Nevirapine—Pain—Etoposide—sarcoma	0.000105	0.0018	CcSEcCtD
Nevirapine—Conjunctivitis—Epirubicin—sarcoma	0.000105	0.00179	CcSEcCtD
Nevirapine—Neutropenia—Doxorubicin—sarcoma	0.000105	0.00179	CcSEcCtD
Nevirapine—Diarrhoea—Vincristine—sarcoma	0.000104	0.00177	CcSEcCtD
Nevirapine—Hepatobiliary disease—Epirubicin—sarcoma	0.000102	0.00175	CcSEcCtD
Nevirapine—Nausea—Thiotepa—sarcoma	0.000102	0.00174	CcSEcCtD
Nevirapine—Feeling abnormal—Etoposide—sarcoma	0.000101	0.00173	CcSEcCtD
Nevirapine—Hyperglycaemia—Doxorubicin—sarcoma	0.000101	0.00173	CcSEcCtD
Nevirapine—Diarrhoea—Mitoxantrone—sarcoma	0.000101	0.00173	CcSEcCtD
Nevirapine—Nausea—Dactinomycin—sarcoma	0.000101	0.00172	CcSEcCtD
Nevirapine—Agranulocytosis—Epirubicin—sarcoma	0.000101	0.00172	CcSEcCtD
Nevirapine—Gastrointestinal pain—Etoposide—sarcoma	0.0001	0.00172	CcSEcCtD
Nevirapine—Stevens-Johnson syndrome—Doxorubicin—sarcoma	9.9e-05	0.00169	CcSEcCtD
Nevirapine—Renal failure—Doxorubicin—sarcoma	9.81e-05	0.00168	CcSEcCtD
Nevirapine—Neuropathy peripheral—Doxorubicin—sarcoma	9.79e-05	0.00167	CcSEcCtD
Nevirapine—Urticaria—Etoposide—sarcoma	9.75e-05	0.00167	CcSEcCtD
Nevirapine—Jaundice—Doxorubicin—sarcoma	9.73e-05	0.00167	CcSEcCtD
Nevirapine—Abdominal pain—Etoposide—sarcoma	9.7e-05	0.00166	CcSEcCtD
Nevirapine—Body temperature increased—Etoposide—sarcoma	9.7e-05	0.00166	CcSEcCtD
Nevirapine—Conjunctivitis—Doxorubicin—sarcoma	9.7e-05	0.00166	CcSEcCtD
Nevirapine—Hepatitis—Epirubicin—sarcoma	9.69e-05	0.00166	CcSEcCtD
Nevirapine—Vomiting—Vincristine—sarcoma	9.64e-05	0.00165	CcSEcCtD
Nevirapine—Rash—Vincristine—sarcoma	9.56e-05	0.00164	CcSEcCtD
Nevirapine—Dermatitis—Vincristine—sarcoma	9.55e-05	0.00163	CcSEcCtD
Nevirapine—Connective tissue disorder—Epirubicin—sarcoma	9.52e-05	0.00163	CcSEcCtD
Nevirapine—Headache—Vincristine—sarcoma	9.49e-05	0.00162	CcSEcCtD
Nevirapine—Hepatobiliary disease—Doxorubicin—sarcoma	9.44e-05	0.00162	CcSEcCtD
Nevirapine—Vomiting—Mitoxantrone—sarcoma	9.38e-05	0.00161	CcSEcCtD
Nevirapine—Agranulocytosis—Doxorubicin—sarcoma	9.32e-05	0.00159	CcSEcCtD
Nevirapine—Rash—Mitoxantrone—sarcoma	9.31e-05	0.00159	CcSEcCtD
Nevirapine—Dermatitis—Mitoxantrone—sarcoma	9.3e-05	0.00159	CcSEcCtD
Nevirapine—Headache—Mitoxantrone—sarcoma	9.25e-05	0.00158	CcSEcCtD
Nevirapine—Erythema multiforme—Epirubicin—sarcoma	9.16e-05	0.00157	CcSEcCtD
Nevirapine—Hypersensitivity—Etoposide—sarcoma	9.04e-05	0.00155	CcSEcCtD
Nevirapine—Nausea—Vincristine—sarcoma	9e-05	0.00154	CcSEcCtD
Nevirapine—Hepatitis—Doxorubicin—sarcoma	8.96e-05	0.00153	CcSEcCtD
Nevirapine—Asthenia—Etoposide—sarcoma	8.81e-05	0.00151	CcSEcCtD
Nevirapine—Connective tissue disorder—Doxorubicin—sarcoma	8.81e-05	0.00151	CcSEcCtD
Nevirapine—Nausea—Mitoxantrone—sarcoma	8.77e-05	0.0015	CcSEcCtD
Nevirapine—Immune system disorder—Epirubicin—sarcoma	8.75e-05	0.0015	CcSEcCtD
Nevirapine—Pruritus—Etoposide—sarcoma	8.69e-05	0.00149	CcSEcCtD
Nevirapine—Erythema multiforme—Doxorubicin—sarcoma	8.47e-05	0.00145	CcSEcCtD
Nevirapine—Erythema—Epirubicin—sarcoma	8.43e-05	0.00144	CcSEcCtD
Nevirapine—Diarrhoea—Etoposide—sarcoma	8.4e-05	0.00144	CcSEcCtD
Nevirapine—Immune system disorder—Doxorubicin—sarcoma	8.1e-05	0.00139	CcSEcCtD
Nevirapine—Ill-defined disorder—Epirubicin—sarcoma	7.82e-05	0.00134	CcSEcCtD
Nevirapine—Vomiting—Etoposide—sarcoma	7.81e-05	0.00134	CcSEcCtD
Nevirapine—Erythema—Doxorubicin—sarcoma	7.8e-05	0.00134	CcSEcCtD
Nevirapine—Anaemia—Epirubicin—sarcoma	7.79e-05	0.00133	CcSEcCtD
Nevirapine—Rash—Etoposide—sarcoma	7.74e-05	0.00132	CcSEcCtD
Nevirapine—Dermatitis—Etoposide—sarcoma	7.73e-05	0.00132	CcSEcCtD
Nevirapine—Headache—Etoposide—sarcoma	7.69e-05	0.00132	CcSEcCtD
Nevirapine—Malaise—Epirubicin—sarcoma	7.6e-05	0.0013	CcSEcCtD
Nevirapine—Nausea—Etoposide—sarcoma	7.29e-05	0.00125	CcSEcCtD
Nevirapine—Ill-defined disorder—Doxorubicin—sarcoma	7.24e-05	0.00124	CcSEcCtD
Nevirapine—Anaemia—Doxorubicin—sarcoma	7.21e-05	0.00123	CcSEcCtD
Nevirapine—Arthralgia—Epirubicin—sarcoma	7.18e-05	0.00123	CcSEcCtD
Nevirapine—Myalgia—Epirubicin—sarcoma	7.18e-05	0.00123	CcSEcCtD
Nevirapine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—sarcoma	7.13e-05	0.00122	CcSEcCtD
Nevirapine—Discomfort—Epirubicin—sarcoma	7.09e-05	0.00121	CcSEcCtD
Nevirapine—Malaise—Doxorubicin—sarcoma	7.04e-05	0.0012	CcSEcCtD
Nevirapine—Anaphylactic shock—Epirubicin—sarcoma	6.88e-05	0.00118	CcSEcCtD
Nevirapine—Oedema—Epirubicin—sarcoma	6.88e-05	0.00118	CcSEcCtD
Nevirapine—Nervous system disorder—Epirubicin—sarcoma	6.75e-05	0.00115	CcSEcCtD
Nevirapine—Thrombocytopenia—Epirubicin—sarcoma	6.74e-05	0.00115	CcSEcCtD
Nevirapine—Skin disorder—Epirubicin—sarcoma	6.68e-05	0.00114	CcSEcCtD
Nevirapine—Myalgia—Doxorubicin—sarcoma	6.64e-05	0.00114	CcSEcCtD
Nevirapine—Arthralgia—Doxorubicin—sarcoma	6.64e-05	0.00114	CcSEcCtD
Nevirapine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—sarcoma	6.6e-05	0.00113	CcSEcCtD
Nevirapine—Discomfort—Doxorubicin—sarcoma	6.56e-05	0.00112	CcSEcCtD
Nevirapine—Anorexia—Epirubicin—sarcoma	6.56e-05	0.00112	CcSEcCtD
Nevirapine—Anaphylactic shock—Doxorubicin—sarcoma	6.37e-05	0.00109	CcSEcCtD
Nevirapine—Oedema—Doxorubicin—sarcoma	6.37e-05	0.00109	CcSEcCtD
Nevirapine—Musculoskeletal discomfort—Epirubicin—sarcoma	6.27e-05	0.00107	CcSEcCtD
Nevirapine—Nervous system disorder—Doxorubicin—sarcoma	6.24e-05	0.00107	CcSEcCtD
Nevirapine—Thrombocytopenia—Doxorubicin—sarcoma	6.23e-05	0.00107	CcSEcCtD
Nevirapine—Skin disorder—Doxorubicin—sarcoma	6.18e-05	0.00106	CcSEcCtD
Nevirapine—Paraesthesia—Epirubicin—sarcoma	6.18e-05	0.00106	CcSEcCtD
Nevirapine—Somnolence—Epirubicin—sarcoma	6.12e-05	0.00105	CcSEcCtD
Nevirapine—Anorexia—Doxorubicin—sarcoma	6.07e-05	0.00104	CcSEcCtD
Nevirapine—Decreased appetite—Epirubicin—sarcoma	5.98e-05	0.00102	CcSEcCtD
Nevirapine—Gastrointestinal disorder—Epirubicin—sarcoma	5.94e-05	0.00102	CcSEcCtD
Nevirapine—Fatigue—Epirubicin—sarcoma	5.93e-05	0.00102	CcSEcCtD
Nevirapine—Pain—Epirubicin—sarcoma	5.88e-05	0.00101	CcSEcCtD
Nevirapine—Musculoskeletal discomfort—Doxorubicin—sarcoma	5.8e-05	0.000993	CcSEcCtD
Nevirapine—Paraesthesia—Doxorubicin—sarcoma	5.72e-05	0.000978	CcSEcCtD
Nevirapine—Feeling abnormal—Epirubicin—sarcoma	5.67e-05	0.00097	CcSEcCtD
Nevirapine—Somnolence—Doxorubicin—sarcoma	5.66e-05	0.000969	CcSEcCtD
Nevirapine—Gastrointestinal pain—Epirubicin—sarcoma	5.63e-05	0.000963	CcSEcCtD
Nevirapine—Decreased appetite—Doxorubicin—sarcoma	5.53e-05	0.000947	CcSEcCtD
Nevirapine—Gastrointestinal disorder—Doxorubicin—sarcoma	5.5e-05	0.000941	CcSEcCtD
Nevirapine—Fatigue—Doxorubicin—sarcoma	5.49e-05	0.000939	CcSEcCtD
Nevirapine—Urticaria—Epirubicin—sarcoma	5.47e-05	0.000936	CcSEcCtD
Nevirapine—Pain—Doxorubicin—sarcoma	5.44e-05	0.000932	CcSEcCtD
Nevirapine—Body temperature increased—Epirubicin—sarcoma	5.44e-05	0.000931	CcSEcCtD
Nevirapine—Abdominal pain—Epirubicin—sarcoma	5.44e-05	0.000931	CcSEcCtD
Nevirapine—Feeling abnormal—Doxorubicin—sarcoma	5.25e-05	0.000898	CcSEcCtD
Nevirapine—Gastrointestinal pain—Doxorubicin—sarcoma	5.21e-05	0.000891	CcSEcCtD
Nevirapine—Hypersensitivity—Epirubicin—sarcoma	5.07e-05	0.000868	CcSEcCtD
Nevirapine—Urticaria—Doxorubicin—sarcoma	5.06e-05	0.000866	CcSEcCtD
Nevirapine—Abdominal pain—Doxorubicin—sarcoma	5.03e-05	0.000861	CcSEcCtD
Nevirapine—Body temperature increased—Doxorubicin—sarcoma	5.03e-05	0.000861	CcSEcCtD
Nevirapine—Asthenia—Epirubicin—sarcoma	4.94e-05	0.000845	CcSEcCtD
Nevirapine—Pruritus—Epirubicin—sarcoma	4.87e-05	0.000833	CcSEcCtD
Nevirapine—Diarrhoea—Epirubicin—sarcoma	4.71e-05	0.000806	CcSEcCtD
Nevirapine—Hypersensitivity—Doxorubicin—sarcoma	4.69e-05	0.000803	CcSEcCtD
Nevirapine—Asthenia—Doxorubicin—sarcoma	4.57e-05	0.000782	CcSEcCtD
Nevirapine—Pruritus—Doxorubicin—sarcoma	4.5e-05	0.000771	CcSEcCtD
Nevirapine—Vomiting—Epirubicin—sarcoma	4.38e-05	0.000749	CcSEcCtD
Nevirapine—Diarrhoea—Doxorubicin—sarcoma	4.36e-05	0.000746	CcSEcCtD
Nevirapine—Rash—Epirubicin—sarcoma	4.34e-05	0.000743	CcSEcCtD
Nevirapine—Dermatitis—Epirubicin—sarcoma	4.33e-05	0.000742	CcSEcCtD
Nevirapine—Headache—Epirubicin—sarcoma	4.31e-05	0.000738	CcSEcCtD
Nevirapine—Nausea—Epirubicin—sarcoma	4.09e-05	0.0007	CcSEcCtD
Nevirapine—Vomiting—Doxorubicin—sarcoma	4.05e-05	0.000693	CcSEcCtD
Nevirapine—Rash—Doxorubicin—sarcoma	4.01e-05	0.000687	CcSEcCtD
Nevirapine—Dermatitis—Doxorubicin—sarcoma	4.01e-05	0.000686	CcSEcCtD
Nevirapine—Headache—Doxorubicin—sarcoma	3.99e-05	0.000683	CcSEcCtD
Nevirapine—Nausea—Doxorubicin—sarcoma	3.78e-05	0.000647	CcSEcCtD
